Results 91 to 100 of about 65,459 (255)
Indonesian Journal of Rheumatology, 2018 Background : Systemic lupus erythematosus (SLE) is a systemic autoimmune disease involving multiple organs including kidney and known as lupus nephritis (LN). Lupus nephritis has a poor prognosis after a 10-years onset, more than 25% will be ended by end
Y H Aini +3 more
doaj +1 more source
Arthritis &Rheumatology, EarlyView.Objective To assess the association between early antimalarial adherence and future acute care utilization and cost in a population‐based cohort of incident rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods All patients with incident RA/SLE and new antimalarial use in British Columbia, Canada, between January 1997 and March 2022
Md Rashedul Hoque +7 more
wiley +1 more source
Revista Colombiana de Nefrología, 2014 Lupus nephritis is one of the most severe manifestations of systemic lupus erythematous. Renal involvement in patients with systemic lupus erythematous is an important cause of morbidity and mortality. The pathogenesis of lupus nephritis involve multiple
Lisandro Pacheco-Lugo +2 more
doaj +1 more source
Correlation of Random Urine Protein Creatinine (P-C) Ratio with 24-Hour Protein Urine in Lupus Nephritis Patients [PDF]
, 2016 Background : Systemic lupus erythematosus (SLE) is a systemic autoimmune disease involving multiple organs including kidney and known as lupus nephritis (LN). Lupus nephritis has a poor prognosis after a 10-years onset, more than 25% will be ended by end
Aini, Y. H. (Y) +3 more
core
Invariant NKT cells and rheumatic disease: Focus on primary sjogren syndrome [PDF]
, 2019 Primary Sjogren syndrome (pSS) is a complex autoimmune disease mainly affecting salivary and lacrimal glands. Several factors contribute to pSS pathogenesis; in particular, innate immunity seems to play a key role in disease etiology.
Barbera L. L. +5 more
core +1 more source
Arthritis &Rheumatology, EarlyView.Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava +8 more
wiley +1 more source
The Clinicopathological Study of Lupus Nephritis
Çukurova Üniversitesi Tıp Fakültesi Dergisi, 2014 Purpose: Lupus nephritis is one of the most serious manifestations of Systemic lupus erythematosis and it is a major cause of morbidity and mortality. The aim of this study is to compare males and females in lupus nephritis presentations.
Raouf Rahim Merza +2 more
doaj
Influence of 1 Alpha, 25-Dihydroxyvitamin D3 on T helper 17 cells and related cytokines in systemic lupus erythematosus [PDF]
, 2015 Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease. Emerging data suggests that T helper 17 (Th17) cells play a pathogenic role in SLE and the increased number of these cells correlates with disease activity.
Abdollahi, N. +7 more
core
Multi‐Omic Profiling Reveals Immune Cell Priming Signature Linked to Lupus Prognosis
Arthritis &Rheumatology, EarlyView.Objective Systemic lupus erythematosus (SLE) is a multiorgan disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith +23 more
wiley +1 more source
Successful Management Strategies for Lupus Nephritis in the Intensive Care Unit: A Case Series
Archives of Anesthesia and Critical CareLupus nephritis, a severe complication of systemic lupus erythematosus (SLE), often leads to significant renal impairment requiring intensive care. The management of lupus nephritis in the intensive care unit of Dr.
Achmad Marwan +2 more
doaj +1 more source